FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      abbv

      ·

      AbbVie Highlights Dermatology Advances at 2026 AAD Meeting

      AbbVie has gained attention following its presentation of extensive dermatology data at the 2026 American Academy of Dermatology meeting. The company showcased long-term results for its treatments Skyrizi and Rinvoq, alongside a new update to its FDA label, which may enhance the marketability of these products.

      As of now, AbbVie shares are priced at $214.98, reflecting a 3.76% increase over the past week and an 8.23% rise over the last month. Year-to-date, the stock has returned 6.25% to investors, while total shareholder returns stand at 8.29% over the past year. These figures indicate a positive trend for the company amidst its ongoing developments in dermatology.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud